BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» Universal picture’s clearer in human RAS inhibition as phase I data from Immuneering screened at AACR
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Universal picture’s clearer in human RAS inhibition as phase I data from Immuneering screened at AACR
April 18, 2023
By
Randy Osborne
No Comments
Immuneering Corp.’s positive pharmacokinetic, pharmacodynamic and safety phase I data with universal RAS inhibitor IMM-1-104 let the company move up the timeline for a recommended phase II dose from previous guidance of mid-2024 to early next year.
BioWorld
Clinical
Conferences
American Association for Cancer Research
Cancer